Quantcast

Latest Craig Mello Stories

2014-08-04 08:27:10

MARLBOROUGH, Mass., Aug. 4, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company will ring the NASDAQ Stock Market closing bell on Friday, August 8, 2014. A live webcast will be available at https://new.livestream.com/nasdaq/live. Logo -...

2014-07-30 08:32:11

MARLBOROUGH, Mass., July 30, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that their third Phase 2a study (RXI-109-1402) with RXI-109, for the reduction of recurrence of hypertrophic scars following elective scar revision surgery, has been initiated. Logo -...

2014-07-07 08:27:41

MARLBOROUGH, Mass., July 7, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the appointment of Dr. Peter Campochiaro to its Scientific Advisory Board. Campochiaro is the George S. and Dolores Dore Eccles Professor of Ophthalmology and Neuroscience in the Johns Hopkins University...

2014-07-02 08:26:20

MARLBOROUGH, Mass., July 2, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced the official opening of its new office and laboratory in the Marlborough Technology Center. The Company will host a ribbon-cutting ceremony on Wednesday, July 9, 2014 from 10:00 -12:00 p.m., at 257 Simarano...

2014-06-24 12:27:23

SAN DIEGO, June 24, 2014 /PRNewswire/ -- Johnson & Johnson today named Dr. Jennifer Doudna of the University of California at Berkeley and the Howard Hughes Medical Institute, and Dr. Emmanuelle Charpentier, of the Hannover Medical School and Helmholtz Centre for Infection Research (HZI), Germany and The Laboratory for Molecular Infection Medicine Sweden (MIMS), Umea University, Sweden, the winners of the 2014 Dr. Paul Janssen Award for Biomedical Research. Their collaboration led to the...

2014-05-27 08:28:04

MARLBOROUGH, Mass., May 27, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the Company's President & CEO, Dr. Geert Cauwenbergh, will present at the Jefferies 2014 Global Healthcare Conference on Tuesday, June 3, 2014 at 8:00 a.m. EDT. Dr. Cauwenbergh will discuss the...

2014-05-22 08:29:07

WESTBOROUGH, Mass., May 22, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that it received the Notice of Allowance from the United States Patent and Trademark Office on its novel, self-delivering RNAi platform (sd?rxRNA®). The patent, titled "Reduced Size Self-Delivering RNAi...

2014-05-02 08:24:37

MARLBOROUGH, Mass., May 2, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced results from the assessment of connective tissue growth factor (CTGF) protein levels following intravitreal injection, of RXI?109 in the eyes of cynomolgus monkeys, as part of a dose-range finding study to...

2014-04-29 12:34:28

MARLBOROUGH, Mass., April 29, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies, today announced that the first patient has enrolled in their Phase 2a study (RXI-109-1401) with RXI-109 for the prevention of keloid recurrence. RXI-109 is an sd-rxRNA® compound that targets connective tissue growth...

2014-04-28 08:31:18

MARLBOROUGH, Mass., April 28, 2014 /PRNewswire/ -- RXi Pharmaceuticals Corporation (NASDAQ: RXII), a biotechnology company focused on discovering, developing and commercializing innovative therapies addressing major unmet medical needs using RNA-targeted technologies today announced that the Company will present at the Association for Research in Vision and Ophthalmology (ARVO) 2014 Annual Meeting. http://photos.prnewswire.com/prnvar/20130917/NE80755LOGO On Sunday, May 4, 2014, from...


Word of the Day
kenspeckle
  • Having so marked an appearance as easily to be recognized.
This word may come from the Swedish 'kanspak,' quick at recognizing persons or things, or else from confusion with 'conspicuous.'